Get the Stockscreener App
16.22
3.31%
0.52
After Hours:
16.22
Rapt Therapeutics Inc stock is traded at $16.22, with a volume of 340.10K.
It is up +3.31% in the last 24 hours and up +48.81% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$15.70
Open:
$15.63
24h Volume:
340.10K
Relative Volume:
3.15
Market Cap:
$268.24M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-5.318
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+25.44%
1M Performance:
+48.81%
6M Performance:
+62.20%
1Y Performance:
+5.05%
1-Day Range:
$15.43
$16.59
1-Week Range:
$12.87
$16.59
52-Week Range:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
16.22 | 233.84M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Rapt Therapeutics (NASDAQ:RAPT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen - Defense World
Is now a turning point for RAPT Therapeutics Inc.July 2025 Patterns & Reliable Volume Spike Alerts - Newser
Analyzing recovery setups for RAPT Therapeutics Inc. investors2025 Short Interest & Verified Technical Signals - Newser
RAPT Therapeutics Inc.’s volatility index tracking explainedTrade Analysis Report & Weekly Momentum Picks - Newser
Using data models to predict RAPT Therapeutics Inc. stock movementJuly 2025 Summary & Technical Pattern Based Buy Signals - Newser
Multi factor analysis applied to RAPT Therapeutics Inc.2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
Using economic indicators to assess RAPT Therapeutics Inc. potentialMarket Risk Analysis & Verified High Yield Trade Plans - Newser
How to recover losses in RAPT Therapeutics Inc. stockEarnings Growth Report & Precise Swing Trade Entry Alerts - Newser
Exit strategy if you’re trapped in RAPT Therapeutics Inc.Portfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
Published on: 2025-09-12 00:37:30 - Newser
Rapt Therapeutics (NASDAQ:RAPT) Raised to "Hold" at Wall Street Zen - MarketBeat
How high can RAPT Therapeutics Inc. stock go2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Key resistance and support levels for RAPT Therapeutics Inc.Fed Meeting & Real-Time Volume Analysis Alerts - Newser
News impact scoring models applied to RAPT Therapeutics Inc.2025 AllTime Highs & Daily Volume Surge Signals - Newser
RAPT Therapeutics Inc. stock momentum explainedEarnings Beat & Precise Buy Zone Identification - Newser
Automated trading signals detected on RAPT Therapeutics Inc.July 2025 Update & Daily Price Action Insights - Newser
Understanding RAPT Therapeutics Inc.’s price movement2025 Short Interest & Reliable Momentum Entry Alerts - Newser
Can momentum traders help lift RAPT Therapeutics Inc.Quarterly Trade Summary & Verified Entry Point Signals - Newser
Earnings visualization tools for RAPT Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical tools2025 Biggest Moves & Verified Entry Point Signals - Newser
Measuring RAPT Therapeutics Inc.’s beta against major indicesJuly 2025 Institutional & Growth Focused Entry Reports - Newser
Applying sector rotation models to RAPT Therapeutics Inc.July 2025 Summary & Proven Capital Preservation Methods - Newser
Is RAPT Therapeutics Inc. trending in predictive chart modelsPortfolio Update Summary & High Conviction Buy Zone Alerts - Newser
Price momentum metrics for RAPT Therapeutics Inc. explainedTake Profit & Weekly High Conviction Trade Ideas - Newser
Ichimoku Cloud Indicates Uncertainty Around RAPT Therapeutics Inc.July 2025 Sector Moves & High Accuracy Swing Trade Signals - beatles.ru
Will RAPT Therapeutics Inc. stock go up soonMarket Performance Report & Capital Protection Trading Alerts - Newser
How to interpret RSI for RAPT Therapeutics Inc. stockTrend Reversal & Free Safe Capital Growth Stock Tips - Newser
What are RAPT Therapeutics Inc.’s earnings expectationsMarket Risk Analysis & Technical Buy Zone Confirmation - خودرو بانک
Is RAPT Therapeutics Inc. stock influenced by commodity pricesIPO Watch & Growth Focused Entry Reports - خودرو بانک
Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street Zen - Defense World
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):